No Data
No Data
Haofan Biotech (301393.SZ) has repurchased 0.75% of its shares.
Haofan Biology (301393.SZ) announced that as of July 31, 2024, the company has accumulated repurchased 811,548 company shares through a repurchase special securities account by means of centralized bidding trading. This accounts for 0.75% of the company's current total share capital, with a highest fill price of 51.50 yuan/share and a lowest fill price of 36.77 yuan/share. The total transaction amount was 33,941,261.68 yuan (excluding transaction fees). The implementation of the company's share repurchase plan is in compliance with relevant laws, regulations, normative documents and provisions.
Haofan Biotech (301393.SZ) granted 0.716 million restricted stocks to 125 incentive recipients.
Haofan Biotechnology (301393.SZ) announced that the company has approved the "About Granting Restrictions to Incentive Objects for the First Time..."
Haofan Biotechnology (301393.SZ): Some directors and executives have completed a shareholding of a total of 0.3803 million shares.
On July 22, Gelonhui reported that Haofan Biology (301393.SZ) received a notice from some of the company's directors and senior management personnel regarding the completion of the shareholding plan. As of the date of the announcement, the above personnel had collectively increased the company's holdings by 0.3803 million shares through the Shenzhen Stock Exchange trading system through centralized bidding, accounting for 0.35% of the total share capital of the company. The total amount of shareholding has reached 15.2242 million yuan, reaching the lower limit of the shareholding plan. The shareholding plan has been completed this time.
Haofan Biotechnology (301393.SZ): Some directors and executives plan to increase their shareholding of the company's shares by 11-22 million yuan, and have already increased their shareholding by a total of 25,400 shares.
On July 4th, Gelunhui reported that some directors and senior management of Haofan Biology (301393.SZ) increased their shareholding in the company through the Shenzhen Stock Exchange trading system in a centralized auction trading manner, buying a total of 25,400 shares with a total transaction amount of 1,010,160.00 yuan. The aforementioned individuals plan to increase their holdings of the company's stocks through the Shenzhen Stock Exchange trading system in accordance with relevant laws and regulations (including centralized auction trading and bulk trading methods) within 6 months from the announcement of this shareholding plan, with a planned amount of increase.
Haofan Biotechnology (301393.SZ): repurchased 0.69% of the shares.
On July 1st, Gelunhui reported that Haofan Biology (301393.SZ) announced that as of June 30, 2024, the company repurchased 745,048 shares of the company through a repurchase special securities account through centralized bidding trading, accounting for 0.69% of the company's current total share capital, with a maximum transaction price of 51.50 yuan/share and a minimum transaction price of 36.77 yuan/share. The total transaction amount was 31,376,940.68 yuan (excluding transaction costs). The company's implementation of share repurchase is in compliance with relevant laws, regulations, normative documents, and the company's share repurchase plan.
Is Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
No Data